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Infectious diseases remain one of the principal causes of morbidity and mortality in
the world. Relevant authorities including the WHO and CDC have expressed serious
concern regarding the continued increase in the development of multidrug resistance
among bacteria. They have also reaffirmed the urgent need for investment in the
discovery and development of new antibiotics and therapeutic approaches to treat
multidrug resistant (MDR) bacteria. The extensive use of antimicrobial compounds in
diverse environments, including farming and healthcare, has been identified as one of
the main causes for the emergence of MDR bacteria. Induced selective pressure has
led bacteria to develop new strategies of defense against these chemicals. Bacteria
can accomplish this by several mechanisms, including enzymatic inactivation of the
target compound; decreased cell permeability; target protection and/or overproduction;
altered target site/enzyme and increased efflux due to over-expression of efflux pumps.
Efflux pumps can be specific for a single substrate or can confer resistance to multiple
antimicrobials by facilitating the extrusion of a broad range of compounds including
antibiotics, heavy metals, biocides and others, from the bacterial cell. To overcome
antimicrobial resistance caused by active efflux, efforts are required to better understand
the fundamentals of drug efflux mechanisms. There is also a need to elucidate how these
mechanisms are regulated and how they respond upon exposure to antimicrobials.
Understanding these will allow the development of combined therapies using efflux
inhibitors together with antibiotics to act on Gram-negative bacteria, such as the
emerging globally disseminated MDR pathogen Escherichia coli ST131 (O25:H4). This
review will summarize the current knowledge on resistance-nodulation-cell division efflux
mechanisms in E. coli, a bacteria responsible for community and hospital-acquired
infections, as well as foodborne outbreaks worldwide.
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Introduction
Escherichia coli is a well-recognized human pathogen. While most strains do not cause disease,
some serotypes are pathogenic. E. coli is the most common cause of UTIs worldwide, but can
Abbreviations: ABC, ATP-binding cassette; EPI, eﬄux pump inhibitor; HGT, horizontal gene transfer; MATE, multidrug
and toxic compound extrusion; MDR, multidrug resistant; MFP, membrane fusion protein; OMP, outer membrane protein;
PMF, proton-motive force; RND, resistance-nodulation-cell division; SMR, small multidrug resistance; UTI, urinary tract
infection.
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also cause bacteraemia and neonatal meningitis as well as
serious food-borne infections. The recent emergence of speciﬁc
serotypes such as O157:H7, responsible for food- and water-
borne outbreaks in Europe (Money et al., 2010; Pennington,
2014) and the U.S. (Centers for Disease Control and Prevention
[CDC], 2006), and the enterohaemorrhagic E. coli O104:H4
that caused the 2011 German outbreak, resulting in 53 deaths
(Radosavljevic et al., 2014), pose a serious threat to public health.
More recently, the worldwide pandemic clone E. coli O25:H4
ST131 has emerged harboring CTX-M-type beta-lactamases as
well as several virulence genes that result in a MDR phenotype
(Olesen et al., 2013).
Treatment of E. coli infections depends on the diagnosis.
Antibiotic therapy normally involves the administration of co-
trimoxazole, nitrofurantoin, or a ﬂuoroquinolone and only
in life-threatening situations a third-generation cephalosporin
can be administrated (Piddock, 2006). The extensive use of
ﬂuoroquinolone-based antimicrobials, has been a major driver in
the development of antibiotic resistant E. coli strains (Cagnacci
et al., 2008; Lamikanra et al., 2011; Matsumura et al., 2013;
Michael et al., 2014).
Antimicrobial resistance has been considered the new
challenge of the 21st century (World Health Organization
(WHO), 2014). The increased level of resistance to antimicrobial
agents has raised serious questions concerning the way in
which these therapeutic compounds are being used (Gilbert
and McBain, 2001). Global organizations have expressed their
concern on this issue, suggesting that increased focus and
eﬀorts are required to address this challenge (World Health
Organization (WHO), 2014). The intensive use of antimicrobial
compounds in the human clinical setting and in animals as
growth promoters (Castanon, 2007) or as a preventive measure
against infection, is considered to be one of the root causes for
selection of resistant bacteria. The constant exposure to sub-
lethal concentrations of antimicrobial compounds, along with
commonly used biocides for disinfection processes, can play
an important role in the selection and emergence of resistant
strains (Andersson and Hughes, 2014; Capita et al., 2014).
The use of certain antibiotics, speciﬁcally ﬂuoroquinolones, has
led to an increase in MDR phenotypes associated with the
overexpression of eﬄux pumps (Wang et al., 2001). In addition,
the presence of naturally occurring heavy metals and the use
of chemicals in agriculture for fertilization of the soil can also
induce the expression of eﬄux pumps in environmental strains
leading to cross-resistance (Peltier et al., 2010). Strengthening our
understanding of these resistance mechanisms will contribute to
the development of new compounds that can ultimately help to
overcome this challenge.
Mechanisms of Antimicrobial Resistance
Gram-negative bacteria, like E. coli, have several mechanisms
of resistance when it comes to surviving the selective pressure
exerted by antimicrobial agents. Some mechanisms can be
deﬁnitive whereas others may reverse when the selective pressure
is released or completely removed. Resistance can occur due to:
(i) accumulation of mutations involved in speciﬁc antimicrobial
targets (e.g., mutations in quinolone resistance-determining
regions (QRDRs) in gyrA, gyrB, parE, and parC genes)
(Moon et al., 2010); (ii) antimicrobial inactivation/modiﬁcation
(e.g., production of β-lactamase enzymes; Poole, 2002); (iii)
acquisition of mobile genetic elements such as plasmids,
transposons, or integrons acquired by HGT (Carraro et al.,
2014; Gillings, 2014); (iv) alteration in the cell wall composition
(e.g., lipopolysaccharide modiﬁcation; Gunn, 2001); (v) reduced
expression of cell wall porins, resulting in decreased inﬂux of
antimicrobials (Masi and Pagès, 2013); and (vi) over-expression
of eﬄux pumps (Wang et al., 2001).
Efflux Pumps
Classicaly, eﬄux pumps can be classiﬁed into ﬁve diﬀerent
families: the ABC superfamily; the major facilitator superfamily
(MFS); the MATE family; the SMR family and the RND family
(Poole, 2007; Li and Nikaido, 2009; Delmar et al., 2014).
Recently, the proteobacterial antimicrobial compound eﬄux
(PACE) family was identiﬁed in some Gram-negative bacteria.
However, E. coli strains do not seem to encode PACE eﬄux
proteins unless carried by mobile genetic elements (Hassan et al.,
2015a,b). While all the eﬄux pump families are well distributed
among Gram-negative bacteria, RND are responsible for the
extrusion of a broad range of compounds (Nikaido and Pagès,
2012). Depending on the eﬄux mechanism diﬀerent energy
sources can be used. ABC transporters for instance, use ATP as
the energy source for extrusion of toxic compounds (Lubelski
et al., 2007), whereas MATE pumps are driven by Na+/H+ drug
antiport systems (Alvarez-Ortega et al., 2013). The MFS, SMR,
and RND pumps are PMF driven, which means that these are
dependent on the pH gradient. For instance, E. coli has been
shown to be able to extrude ethidium bromide more eﬃciently
at lower pH values when compared to higher pH values (Martins
et al., 2009; Amaral et al., 2011).
RND General Structure and Substrates
Resistance-nodulation-cell division transporters operate as part
of a tripartite system composed of the RND pump located in the
inner membrane, a periplasmic adaptor protein from the MFP
family and an OMP belonging to the outer membrane factor
(OMF) family located in the outer membrane (Nikaido, 2011).
The OMP TolC, for example, works in combination with other
RND, ABC, and MFS eﬄux pumps (Tanabe et al., 2009; Turlin
et al., 2014). The absence of any of these components renders the
entire complex non-functional. Nonetheless, the eﬄux systems
show a cooperative interaction between them and can act
sequentially when one fails (Lee et al., 2000; Tal and Schuldiner,
2009). RND transporters can be classiﬁed into two diﬀerent
subfamilies according to their substrates, the hydrophobic and
amphiphilic eﬄux RND (HAE-RND) family and the heavy
metal eﬄux RND (HME-RND) family (Nies, 2003). In E. coli
there are ﬁve eﬄux transporters that belong to the HAE-RND
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subfamily, AcrAB (Tikhonova and Zgurskaya, 2004; Pos, 2009),
AcrAD (Rosenberg et al., 2000; Elkins and Nikaido, 2002), AcrEF
(Nishino and Yamaguchi, 2001), MdtAB (Baranova and Nikaido,
2002; Nagakubo et al., 2002), and MdtEF (Kobayashi et al., 2006;
Zhang et al., 2011). In contrast, there is only one eﬄux transporter
that belongs to the HME-RND, the CusCFBA (Su et al., 2011a;
Chacón et al., 2014; Delmar et al., 2014).
Acriflavine (Acr) Efflux System
AcrAB is encoded in a single operon for the RND and the MFP,
under the control of the transcriptional repressor, AcrR and
AcrS (Wang et al., 2001; Hirakawa et al., 2008; Figure 1). SdiA
(Wei et al., 2001) and CpxRA (Yang et al., 2014) have also been
shown to regulate expression of acrAB. The outer membrane
component, TolC, is coded elsewhere on the chromosome
(Fralick, 1996) and is part of themarA/soxS/rob regulon (Warner
and Levy, 2010).
In the last years, there has been more evidence favoring a
stoichiometry of 3:6:3, comprising an AcrB trimer, an AcrA
hexamer and a TolC trimer (Tikhonova et al., 2011; Xu et al.,
2011; Du et al., 2014). However, the functional stoichiometry
remains unclear and under some controversy (Zgurskaya and
Nikaido, 2000; Fernandez-Recio et al., 2004; Symmons et al.,
2009).
The RND protein AcrB is composed of 1,049 amino acids
and is distributed throughout the transmembrane domain and
the large periplasmic domain (Husain and Nikaido, 2010;
Figure 2A). The ﬁrst symmetrical crystal structure for AcrB
protein was resolved by Murakami et al. (2002) at a 3.5
Å resolution in which three AcrB protomers were organized
as a homotrimer. Co-crystallization of AcrB with several
ligands (including 6-rhodamine 6G, ethidium, dequalinium
and ciproﬂoxacin) showed that these ligands bind near the
transmembrane domain and in various positions within the
binding pocket. The binding is established primarily through
hydrophobic, aromatic stacking, and van der Waals interactions
(Yu et al., 2003). Asymmetric crystal structures of AcrB were later
resolved using minocycline, doxorubicin (Murakami et al., 2006),
ethidium, dequalinium (Seeger et al., 2006), and designed ankyrin
repeat proteins (DARPins), the latter being an inhibitor designed
speciﬁcally for AcrB, as a substrate (Sennhauser et al., 2007).
The asymmetric structure obtained indicated that each
protomer takes on a diﬀerent conformation, which is related to
a diﬀerent stage of the ligand binding and extrusion mechanism
(Figure 2B). One of the monomers presents a loose (L)
conformation. Here, the substrates can enter from three diﬀerent
open channels (Figures 2A,B; 1, 2, and 3). Substrates can enter
via the lower external depression or cleft (Figures 2A,B; 1)
in the periplasmic side close to the outer leaﬂet away from
the membrane surface. Substrates can also enter through the
vestibule, located between the protomers (Figures 2A,B; 2),
facing toward the periplasm, close to the external surface of the
membrane bilayer (Murakami et al., 2006; Sennhauser et al.,
2007). The last channel (Figures 2A,B; 3) in which substrates
FIGURE 1 | A schematic representation of the position and size of the
resistance-nodulation-cell division (RND) efflux pump genes in the
genome of Escherichia coli str. K-12 substr. W3110. RND genes are
described in red, membrane fusion protein (MFP) in green, and the outer
membrane protein (OMP) in blue. Small proteins such as AcrZ and CusF are
indicated in beige. Regulators are marked with the color yellow.
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FIGURE 2 | A model representation of AcrABZ-TolC efflux pump. (A) Side
view of a schematic model of a tripartite efflux system in Gram-negative
bacteria. RND protein AcrB is described in red, the MFP, AcrA is indicated in
green, and the OMP, TolC in blue. The small protein AcrZ is colored in beige.
OM, outer membrane; IM, inner membrane. (B) Top view of the different stages
of the ligand extrusion mechanism in AcrB RND efflux pump. Each color
represents a protomer of the AcrB protein. 1: lower external depression or cleft
channel; 2: vestibule channel; 3: central cavity channel; 4: central cavity; 5:
proximal binding pocket; 6: distal binding pocket; 7: central funnel. LMMS, low
molecular mass substrates; HMMS, high molecular mass substrates. Adapted
from (Murakami et al., 2002, 2006; Seeger et al., 2006; Husain et al., 2011;
Nakashima et al., 2011).
can enter is located directly in the central cavity (Figures 2A,B;
4; Husain and Nikaido, 2010; Husain et al., 2011). The central
cavity is involved in the transport of substrates from the cytosol
(Yu et al., 2003). Once the substrate that derives from the
cytoplasm or the periplasm binds to one of the channels, the
binding pocket expands to accommodate the substrate. Once
expanded, the substrate moves through the uptake channel, or
tunnel, binding to the diﬀerent locations within the multisite
binding pocket (Murakami et al., 2006). The binding step
occurs in the interior of the periplasmic domain at the tight
protomer (T). High molecular mass substrates (HMMS), such
as rifampicin or erythromycin, bind to the proximal binding
pocket (Figures 2A,B; 5; Nakashima et al., 2011). Low molecular
mass substrates (LMMS), as minocycline or doxorubicin, on
the other hand, travel through the proximal pocket and bind
further up on the distal pocket (Figures 2A,B; 6; Murakami
et al., 2006). The extrusion of the substrate is then dependent
on the last open protomer (O) of the AcrB trimer. Here, the
conformation of the central helix of the protomer is changed
due to the protonation closing the open channels and opening
the gate into the central funnel (Figures 2A,B; 7). Finally, the
substrate is pushed out to the central funnel by the shrinking of
the binding pocket where it will bind to the TolC domain and is
subsequently extruded from the bacterial cell (Murakami et al.,
2006; Seeger et al., 2006; Sennhauser et al., 2007; Nikaido and
Pagès, 2012). An in depth review on the structure and transport
of AcrB can be found elsewhere (Yu et al., 2003; Pos, 2009;
Husain and Nikaido, 2010; Nakashima et al., 2011; Li et al.,
2015).
The MFP AcrA (Figure 2A) is anchored to the inner
membrane by the N-terminal lipid modiﬁcation. This protein
is composed of a membrane proximal (MP) domain, a β-barrel
domain, a lipoyl domain and an α-hairpin domain (Symmons
et al., 2009). The later domain is known to interact with the
outer membrane TolC whereas the ﬁrst three domains are
responsible for the interaction with AcrB (Elkins and Nikaido,
2003; Lobedanz et al., 2007; Kim et al., 2010a). Other studies
show that AcrA is able to bind both RND and OMP proteins
independently with nanomolar aﬃnity (Tikhonova et al., 2011).
AcrA oligomerisation and pH proved to be essential for AcrB
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aﬃnity (Tikhonova et al., 2009, 2011; Xu et al., 2011; Kim et al.,
2010a, 2015). However, some thermodynamic interaction studies
have shown that AcrA-TolC binds spontaneously whereas the
interaction between AcrB and TolC is not thermodynamically
favored (Touzé et al., 2004). AcrA function as a dimeric
unit and each AcrA dimer has a propensity to form a
trimer when in contact with an AcrB protomer, establishing
a AcrA–AcrB stoichiometry of 6:3 (Tikhonova et al., 2011;
Xu et al., 2011). The AcrA MP domain is also known to
play an important role in the assembly of the tripartite eﬄux
system (Ge et al., 2009; Weeks et al., 2010; Tikhonova et al.,
2011).
The TolC outer membrane channel is made up of three TolC
protomers that form a cannon shaped tunnel of 140 Å (Koronakis
et al., 2000; Figure 2A). This channel makes the connection
between the periplasmic space and the cell exterior through
the outer membrane (Hinchliﬀe et al., 2013). The 12-stranded
β-barrel, formed by four β-strands from each TolC protomer,
are constitutively open to the external medium, whereas the
periplasmic α-barrel comprises 12 α-helices in an antiparallel
arrangement, four from each protomer (Koronakis et al., 2000).
Here an aspartate ring of residues establish a constriction that
eﬀectively closes the TolC pore to substrates (Higgins et al.,
2004). TolC assumes a closed conformation when inactive. Only
a small portion of TolC is used to support eﬄux activity and
it is expressed at lower levels. The expression of AcrAB has
no eﬀect on TolC expression (Krishnamoorthy et al., 2013).
The TolC protein is also part of others eﬄux systems such
as the EmrAB-TolC or the MacAB-TolC of the MFS and
ABC superfamilies, respectively, (Tanabe et al., 2009; Lu and
Zgurskaya, 2012).
The assembly mechanism of the tripartite system is not
fully understood, to date. Therefore, several models have been
generated over the years. The Adaptor Wrapping Model, assumes
that AcrB and TolC connect individually; plasmon surface
resonance data also conﬁrms this interaction (Tikhonova et al.,
2011). TolC binds to the AcrB crown through the outer helices
H3 and H4 (Weeks et al., 2010). As a result of this interaction, the
inner helices H7 andH8 relax exposing the intraprotomer groove.
The exposed intraprotomer groove is a high-aﬃnity site for AcrA
(Bavro et al., 2008). Binding to the exposed grooves of TolC cause
alterations in the MP domain of AcrA (Krishnamoorthy et al.,
2013); these conformational changes induce the opening of the
TolC (Bavro et al., 2008). However, the partial opening of TolC,
using a TolC mutant, rendered the tripartite system unstable
and lead to disassembly of AcrAB-TolC eﬄux pump (Tikhonova
et al., 2011). To date, there seems to be no consensus as to how
the opening of TolC actually occurs.
The other model generated over the last years is the Adaptor
Bridging Model. This model assumes no direct interaction
between AcrB and TolC (Kim et al., 2010a; Xu et al., 2012;
Du et al., 2014). Thermodynamic data has also shown that
this interaction is not favored (Touzé et al., 2004). This model
was generated based on the structure of other eﬄux systems
with similar tripartite composition to AcrAB-TolC (Yum et al.,
2009; Xu et al., 2012). These models also claim the fact that
cross-linking interaction with cysteine only indicates that the
protein are in close proximity with each other; it does not
mean that they are stable (Touzé et al., 2004). In fact, attempts
at cross-linking have shown that the proteins do not form
functional complexes (Kim et al., 2010a; Xu et al., 2011), or
barely functional complexes (Du et al., 2014). In this model,
AcrB and TolC are bridged in the periplasm through an AcrA
hexamer (Xu et al., 2011; Du et al., 2014; Kim et al., 2015).
When packed, AcrA protomers generate a funnel-like structure
with a sealed central channel, closed to the periplasm (Du
et al., 2014). The AcrA α-helical hairpins interact with the
periplasmic ends of the α-helical coiled coils of TolC in an
intermeshing-like cogwheel structure (Xu et al., 2011; Kim
et al., 2015). The β-barrel and lipoyl domains of AcrA form a
triangular hollow chamber, who’s bottom opens into the funnel
of AcrB (Xu et al., 2011; Du et al., 2014). The interaction
with the α-helical hairpins of AcrA change the conformation
of the TolC hexamer to the open form (Du et al., 2014). TolC
remains in this open form throughout the entire transport
cycle.
Recently, a small protein AcrZ, formerly designated YbhT,
was shown to interact with AcrB through the inner membrane
(Hobbs et al., 2012). The acrZ gene is co-regulated by MarA,
Rob and SoxS, the same regulators of AcrAB eﬄux pump.
The gene is located between two molybdenum-ﬂanking
operons involved in molybdenum uptake and the regulation
of molybdenum cofactor synthesis (see Figure 1). Structures
such as tetracycline or acriﬂavine, or other substrates with
several polycyclic features, are suggestive of the molybdenum
cofactor. Enzymes such as xanthine dehydrogenase and
aldehyde oxidoreductase (that requires a molybdenum cofactor)
detoxify compounds that may be extruded through AcrB
RND pump (Hobbs et al., 2012). The AcrZ protein was
shown to help AcrAB-TolC complex to recognize and export
chloramphenicol, tetracycline and puromycin (Hobbs et al.,
2012). These authors suggested that AcrZ might trigger
some conformational changes in the periplasmic domain
aﬀecting the recognition and capture of substrates with lower
hydrophobicity.
AcrAB-TolC eﬄux system is known to be responsible for
the extrusion of a broad range of compounds such as lipophilic
antimicrobial drugs, i.e., penicillin G, cloxacillin, nafcillin,
macrolides, novobiocin, linezolid, and fusidic acid (Nikaido,
2011); antibiotics (such as ﬂuoroquinolones, cephalosporins,
tetracyclines; Nikaido and Takatsuka, 2009); various dyes (i.e.,
crystal violet, acridine, acriﬂavine, ethidium, 6-rhodamine 6G);
detergents [sodium dodecyl sulfate (SDS) and Triton X-100;
Pos, 2009]; organic solvents (hexane, cyclohexane); steroid
hormones (bile acids, estradiol, and progesterone) (Elkins and
Mullis, 2006); essential oils (Fadli et al., 2014); and others
(see Table 1). A common feature of all the substrates is
that, to some extent, all contain lipophilic domains (Nikaido,
1996). However, the way these substrates interact with the
phospholipid bilayer and the RND pumps is not yet completely
deﬁned.
AcrD, another acriﬂavine RND-type eﬄux pump, plays a
similar role to AcrB. In contrast with the other acriﬂavine
resistance eﬄux systems, acrD does not form an operon with
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TABLE 1 | Resistance-nodulation-cell division (RND) efflux pumps substrates and regulators.
Efflux pump Substrates RND Regulator(s) Reference
AcrAB-TolC β-lactams, quinolones, tetracyclines, tigecycline,
chloramphenicol, steroid hormones, lincosamides,
benzene, cyclohexane, SDS, Triton X-100, rifampicin,
bile salts, free fatty acids, geraniol, enterobactin,
triclosan, chlorhexidine, quaternary ammonium
compounds, acriflavin, ethidium bromide
AcrR
AcrS
SdiA
MarRAB
Rob
SoxS
CpxRA
Perreten et al. (2001), Wang et al. (2001), Rahmati et al. (2002),
Rosenberg et al. (2003), Hirata et al. (2004), Elkins and Mullis
(2006), Poole (2007), Hirakawa et al. (2008), Lennen et al. (2013),
Shah et al. (2013), Horiyama and Nishino (2014)
AcrAD-TolC Aminoglycosides, steroid hormones, enterobactin,
β-lactams, quinolones, Sodium dodecyl sulfate (SDS),
deoxycholate
BaeR
SdiA
CpxRA
Nishino and Yamaguchi (2001), Wei et al. (2001), Hirakawa et al.
(2003), Elkins and Mullis (2006), Poole (2007), Nishino et al. (2010),
Horiyama and Nishino (2014), Kobayashi et al. (2014)
AcrEF-TolC Quinolones, tigecycline, solvents H-NS
SdiA
Jellen-Ritter and Kern (2001), Kobayashi et al. (2001), Wei et al.
(2001), Hirata et al. (2004), Nishino and Yamaguchi (2004)
MdtABC-TolC Novobiocin, bile salts, enterobactin, quinolones,
fosfomycin, benzalkonium, SDS, zinc, myricetin
BaeSR
CpxRA
Nishino and Yamaguchi (2001), Baranova and Nikaido (2002),
Nagakubo et al. (2002), Hirakawa et al. (2003), Nishino et al. (2010),
Kim and Nikaido (2012), Wang and Fierke (2013), Horiyama and
Nishino (2014)
MdtEF-TolC Erythromycin, doxorubicin, benzalkonium, SDS,
deoxycholate, crystal violet, ethidium bromide, nitrosyl
indole, rhodamine 6G, tetraphenylphosphonium
bromide, free fatty acids
H-NS
YdeO
CRP
GadX
ArcBA
GadE
EvgAS
RpoS
DsrA
Nishino and Yamaguchi (2001, 2002, 2004), Kobayashi et al.
(2006), Nishino et al. (2008a,b, 2009, 2011), Zhang et al. (2011),
Deng et al. (2013), Lennen et al. (2013)
CusCFBA Silver, copper, fosfomycin, ethionamide, dinitrobenzene CusSR Nishino and Yamaguchi (2001), Conroy et al. (2010), Kim et al.
(2011), Gudipaty et al. (2012)
the MFP gene acrA (Figure 1; Rosenberg et al., 2000). This
gene is under the control of the regulons BaeR (Hirakawa
et al., 2003), SdiA (Wei et al., 2001), and CpxRA (Nishino
et al., 2010). With 1,037 amino acids and 66.1% homology with
AcrB, AcrAD-TolC has a diﬀerent substrate speciﬁcity mainly for
hydrophilic substrates such as aminoglycosides (Rosenberg et al.,
2000), negatively charged β-lactams (Kobayashi et al., 2014) and
mild speciﬁcity for SDS, deoxycholate, novobiocin, cholic acid
(Nishino and Yamaguchi, 2001), progesterone (Elkins andMullis,
2006), and others. AcrD was used as a model to understand
how RND pumps capture their substrates. This eﬄux pump was
shown to capture aminoglycosides from both the periplasm and
the cytoplasm (Aires and Nikaido, 2005). The results were then
extrapolated in part to AcrB due to the close homology between
both proteins. A chimeric study between AcrB and AcrD showed
that the replacement of the two large external loops of AcrD
with the equivalent loops of AcrB altered the substrate range
of AcrD to a broader one, more typical of AcrB. Conversely,
the replacement of the two large loops in AcrB with those of
AcrD lead to an eﬄux pump that had a narrower substrate
range, similar to that of an AcrD eﬄux pump. This demonstrated
the importance these large periplasmic loops of AcrB and AcrD
play in the substrate range of these pumps (Elkins and Nikaido,
2002).
AcrEF-TolC is also part of the acriﬂavine eﬄux system.
The eﬄux system is encoded in an operon wherein the RND
acrF gene is located together with the MFP gene acrE, with
both genes under the control of the regulator sdiA (Wei et al.,
2001). Histone-like proteins (e.g., H-NS, HU, IHF) are a key
component of the bacterial nucleoid and play an important
role in global gene regulation (Nishino and Yamaguchi, 2004).
The inactivation of H-NS increases the expression of AcrEF,
indicating that H-NS represses the expression of AcrEF. The
RND protein AcrF has 1,034 amino acids and 77.6% homology
with AcrB, whereas AcrE has 385 amino acids and 69.3%
homology with AcrA. Due to the close homology observed it
is predicted that this system assembles in a similar manner as
AcrAB.
The complex, AcrEF is postulated to be functionally identical
to AcrAB due to its similar broad substrate range (Nishino
and Yamaguchi, 2001). Nonetheless, acrEF expression is very
low under laboratory conditions (Lau and Zgurskaya, 2005).
Deletion acrEF produced no observable eﬀect on the resistance
phenotype in E. coli (Sulavik et al., 2001). Currently, is
still unclear under what physiologic conditions AcrEF is
expressed.
The recombination of insertion sequence (IS) elements
upstream of the acrEF operon increases the expression of the
eﬄux system (Misra et al., 2015). Using an acrB mutant with
increased expression of AcrEF the hypersentivity to solvents
generated by the mutant was supressed (Kobayashi et al., 2001);
the same pattern was also seen for ﬂuoroquinolones (Jellen-Ritter
and Kern, 2001).
The acriﬂavine eﬄux system is one of the most studied systems
and presents a broad range of substrate resistance. Understanding
how these tripartite systems act in diﬀerent conditions has given
us some insights that could be used to design and develop new
inhibitor compounds.
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Multidrug Transport (Mdt) Efflux System
MdtABC-TolC is encoded in a single operon under the control
of the two-component regulatory system, BaeSR (Figure 1;
Nagakubo et al., 2002). During envelope stress this eﬄux system
can also be activated by the CpxRA regulon (Nishino et al., 2010).
The mdtD gene, which is also part of this operon, codes for a
MFS transporter (Baranova andNikaido, 2002). Nonetheless, this
protein is not necessary for increased resistance to antimicrobials.
Recently, MdtD has been associated with eﬄux of iron and
citrate, being renamed as IceT (Frawley et al., 2013). MdtABC-
TolC eﬄux system is responsible for the extrusion of substrates
such as novobiocin, bile salts (Nagakubo et al., 2002), quinolones,
fosfomycin, detergents (Nishino and Yamaguchi, 2001), zinc
(Wang and Fierke, 2013), and myricetin (Kim and Nikaido,
2012).
The MdtABC-TolC eﬄux system presents a heterotrimeric
conformation for the RND pump, in contrast to the pattern
seen for AcrB, AcrD, AcrF, and CusA. The RND pump
MdtBC, formerly known as YegNO, is composed by two
MdtB protomers of 1,040 amino acids each, and one MdtC
protomer with 1,025 residues (Kim et al., 2010b). Remarkably,
these two protomers only show 49% similarity between them
(Kim and Nikaido, 2012). In this case, each protomer has a
speciﬁc function; MdtC is likely to be involved in substrate
binding and extrusion whereas MdtB has been shown to induce
conformational changes in the trimer, when the substrate binds
to MdtC, leading to proton translocation (Kim and Nikaido,
2012). There is little structural information about this eﬄux
system as there is no crystallographic data available to date.
A homology model based on the AcrB crystal structure showed
that MdtC has a broad tunnel beginning at the external cleft
and continuing all the way to the interior edge of the binding
pocket. The tunnel appears to narrow before it reaches the
binding pocket (Kim and Nikaido, 2012). Based on this model,
a substrate mechanism was predicted in which the substrate
binds ﬁrst to the peripheral site near the cleft. The binding
of the substrate may induce proton translocation through the
MdtB subunit(s), which will cause conformational changes
mainly at the opening of the tunnel and the expansion of
the binding pocket in the MdtC protomer, in a manner
similar to what is observed in AcrAB (Kim and Nikaido,
2012).
MdtEF-TolC is the other known multidrug eﬄux system in
this family, formerly referred to as YhiUV-TolC. The genes
encoding this eﬄux system are located in an operon (Figure 1)
under the control of gadX (Nishino et al., 2008b), gadY
(Kobayashi et al., 2006) and gadE (Deng et al., 2013), which
are regulators of acid resistance (Table 1). This operon can
be activated in complex cascades or directly by several major
regulators, such as EvgAS (Nishino and Yamaguchi, 2002); ArcBA
(Deng et al., 2013); RpoS (Kobayashi et al., 2006); YedO (Nishino
et al., 2009); or by the MdtEF repressor of cyclic AMP receptor
protein (Nishino et al., 2008a), or the histone-like protein H-NS
(Nishino and Yamaguchi, 2004). MdtEF eﬄux pump function is
related with cell growth, its maximal expression level is achieved
in late stationary phase of E. coli growth (Kobayashi et al., 2006).
Proteins MdtE and MdtF share 55 and 71% homology with AcrA
and AcrB, respectively. Due to this fact the same conformational
structure was assumed for the purpose of this review. MdtEF
is known to induce resistance to oxacillin, cloxacillin, nafcillin,
erythromycin, rhodamine 6G, and SDS under the controlled
expression of the regulator, GadX (Nishino et al., 2008b). It can
also induce resistance to benzalkonium, deoxycholate (Nishino
and Yamaguchi, 2001), indole (Zhang et al., 2011), and others.
In E. coli, MdtEF has an important role in cell growth under
anaerobic conditions (Zhang et al., 2011). MdtEF mutants have
shown susceptibility to indole nitrosative derivatives, a by-
product formed when the bacterium metabolizes nitrate under
anaerobic conditions. It was also observed that under respiratory
stress MdtEF was able to extrude erythromycin (Zhang et al.,
2011).
Copper Transporting (Cus) Efflux System
The CusCFBA system is the only HME-RND identiﬁed in E. coli
to date. It is responsible for the extrusion of silver (Ag+) and
copper (Cu+). Although recognized for the extrusion of these
two ions it was also found to induce resistance to fosfomycin
(Nishino and Yamaguchi, 2001), dinitrophenol, dinitrobenzene,
and ethionamide (Conroy et al., 2010). The cus genes, cusCFBA,
are all located in the same operon (Figure 1) under the control
of cusR and cusS encoding a response regulator and a histidine
kinase, respectively, (Gudipaty et al., 2012). This eﬄux system
plays an important role in Cu+ homeostasis in bacterial cells
(Rademacher and Masepohl, 2012). The Cus system, like all
the RND eﬄux pumps presents a tripartite structure or a
tetrapartite structure, if CusF is taken into consideration. For
the purpose of this review, the system will be considered as a
tripartite system, as was the case for the AcrAB-TolC system and
AcrZ.
The system is composed by the RND eﬄux pump (CusA);
the MFP (CusB); and by the OMP (CusC). These proteins
assemble together in a stoichiometry identical to the AcrB,
CusA(3):CusB(6):CusC(3) (Su et al., 2011b; Delmar et al.,
2014).
With 1,047 amino acids CusA was ﬁrst resolved at 3.5 Å
suggesting a homotrimer conﬁguration. Each protomer is
composed by 12 transmembrane α-helices, four of each
protruding into the cytoplasm and two into the periplasm (Long
et al., 2010). Consequently, Cu+ and Ag+ were found to bind
to the residues M573, M623, and M672 located at the bottom of
the periplasmic cleft together with other conserved residues (Su
et al., 2012). Once bound, both Cu+ and Ag+ appeared to induce
signiﬁcant conformational changes in both the periplasmic and
transmembrane domains of CusA (Long et al., 2010; Su et al.,
2012). The changes seemed to create a doorway for metal ions
to enter the periplasmic domain of the pump. The cleft, which is
initially closed, is open in the presence of Ag+ or Cu+ revealing
the binding site. At the same time the changes caused by the
binding may also relate to transmembrane signaling, which are
thought to initiate proton translocation across the membrane
(Delmar et al., 2013).
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Four distinct methionine pairs have been identiﬁed on
the inside of the channel formed by each protomer of the
CusA pump. Three of these pairs: M410–M501, M403–M486,
and M391–M1009 are found below the binding site in the
transmembrane domain, and one, M271–M755, is located at the
bottom of the periplasmic funnel. This channel, together with
the three-methionine residues from the binding site, spans the
entire length of each protomer. This represents a pathway for
the transport of metal ions (Su et al., 2011a). Metal ions can
enter through the binding site inside the cleft directly through
the periplasmic cleft or via the cytoplasm through the methionine
pairs within the transmembrane region. The metal ions bound at
the methionine pair in the periplasmic funnel are released into
the central funnel following the methionine pathway (Su et al.,
2011a).
The second component of the Cus eﬄux system is the
periplasmic membrane protein CusB. With 407 amino acids, it
was ﬁrst resolved at 3.4 Å (Su et al., 2009). Based on the crystal
structure, it was initially thought to form a dimer. Subsequently,
it has been shown that CusB forms a hexameric channel directly
above the periplasmic domain of CusA (Su et al., 2011b; Long
et al., 2012). The structure of the CusB hexamer mimics an
inverted funnel and follows the same stoichiometry as AcrA,
AcrB(3):AcrA(6):TolC(3).
Four domains, three β-domains and one α-helical domain,
compose each protomer of CusB. The ﬁrst β-domain is located
above the outer-leaﬂet of the inner membrane and it interacts
directly with the CusA through the periplasmic domain (Su
et al., 2011a). Both Ag+ and Cu+ bind to the CusB domain-1
at the residue positions M324, F358, and R368. The hexameric
CusB channel is primarily created by β-barrels in the lower
half, whereas the upper half is an entirely α-helical tunnel. The
inner surface of the channel is predominantly negatively charged,
which suggests a capacity to bind positively charged metal ions
(Delmar et al., 2014). Methionine residues M21, M36, and M38
of CusB are most likely Cu+ and Ag+ binding sites (Bagai
et al., 2007). These residues are located outside the periplasmic
cleft of CusA, the same cleft that was shown to harbor the
three-methionine binding sites. Therefore, CusBmay transfer the
bound metal ions at this location into the periplasmic cleft of
CusA for extrusion (Su et al., 2011b).
CusF is a small chaperone protein of 110 amino acids and was
ﬁrst crystallized in 2005 at 1.5 Å resolution (Loftin et al., 2005).
CusF exhibits a small ﬁve-stranded β-barrel composed of two
antiparallel, three-stranded β-sheets packed orthogonally. Three
conserved residuesH36,M47,M49, andW44 located in β-strands
2 and 3, have been shown to interact with Cu+ and Ag+ (Loftin
et al., 2007; Xue et al., 2008). Nativemass spectrometry has shown
that the N-terminal region of CusB can acquire Cu+ from CusF
(Mealman et al., 2012). It was proposed that under anaerobic
conditions, due to the accumulation of Cu+ and Ag+ in the
periplasm, there is a strong up-regulation of the metal chaperone
CusF and that the former would work as a scavenger of metal
ions and help ﬁll all the available CusB binding sites (Kim et al.,
2011; Chacón et al., 2014). The proposed model also suggests that
CusB activates and deactivates the CusA pump depending on the
ion levels in the periplasmic space. CusF interaction with CusB
appears to have an activating eﬀect in this cascade, initiated by
the opening of the periplasmic cleft.
The OMP of the Cus system, CusC, with 460 amino acids,
was ﬁrst crystallized in 2011 at a resolution of 2.3 Å (Kulathila
et al., 2011). CusC assembles as a homotrimer creating a large
cylindrical channel, the largest found in the outer membrane
family. Structurally, the cannon shape is identical to TolC and
OprM, however, CusC is believed to work only in the Cus
eﬄux system (Delmar et al., 2014). The interior surface of the
channel is highly electronegative allowing for the binding of
positively charge ligands. The transmembrane domains appear to
be open at the bottom entrance, whereas it appears to be closed
at the far end by van der Waals interactions. Each protomer
contains a tri-acylated N-terminal cysteine residue shown to
be covalently linked to the outer membrane via a thioester
bond (Kulathila et al., 2011; Delmar et al., 2013). In a docking
model, CusC appears to interact with CusAB at the interior of
the upper half of the channel formed by the α-helical domain
of CusB, primarily through coiled-coil interaction (Long et al.,
2012).
The Cus system is well characterized for Cu+ and Ag+,
nonetheless, the mechanism of action for other substrates needs
to be further characterized.
Functions of RND Efflux Pumps in E. coli
During growth, E. coli produces secondary metabolites that
can be toxic to the cell. There are three ways of eliminating
these metabolites. This can be achieved by inclusion of
these metabolites into a second metabolic pathway; enzymatic
degradation to non-toxic metabolites or extrusion of metabolites
generated to the external environment. RND eﬄux pumps can
also contribute to eliminate secondary metabolites. In a study
using deleted genes for enterobactin biosynthesis (entA and
entE), gluconeogenesis (glpX), cysteine biosynthesis (cysH), and
purine biosynthesis (purA), the results showed no or diminished
eﬀect on the AcrAB promoter in an AcrB mutant strain (Ruiz and
Levy, 2014). This suggests that this eﬄux pump is able to extrude
compounds that are toxic or have a signaling role. In E. coli,
the secretion of iron-chelating siderophore enterobactin from
the periplasm is associated with AcrAB, AcrAD, and MdtABC
RND eﬄux pumps (Horiyama and Nishino, 2014). Using a triple
mutant acrB, acrD, and mdtABC a signiﬁcant reduction in the
extrusion of enterobactin from the cells was noted. Secretion of
metabolites is therefore important for the proper development
of the cell. Most of these metabolites regulate master regulators
such as MarA or SoxS (Amaral et al., 2011). Therefore, based on
these observations the sensor dosage hypothesis was developed.
This hypothesis contemplates a homeostatic loop in which
the intercellular concentration of metabolites reaches a certain
threshold, at which they activate transcriptional regulators such
as MarA, SoxS, and Rob (Rosner and Martin, 2009; Amaral
et al., 2011). These regulators activate their target genes encoding
proteins that function in the extrusion mechanism. When the
basal levels of these metabolites are restored, the expression of
the transcriptional regulators is restored also.
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Considering the human host, in a food-borne infection
scenario, E. coli has to transit through the human gastrointestinal
(GI) tract in order to successfully colonize the intestine. To
accomplish this it must survive pH variations and toxicity of
the diﬀerent environments. The presence of bile acids poses an
additional barrier to bacterial survival. Bile acids are released
into the duodenum and are present along the GI tract, aﬀecting
the cell membrane, and DNA of E. coli (Merritt and Donaldson,
2009). Bile salts are known to induce the expression of AcrAB-
TolC in E. coli (Thanassi et al., 1997; Rosenberg et al., 2003)
allowing the bacteria to survive in such environments. Other
mammalian steroid hormones that are released in bile, also
activate AcrB, AcrD, and MdtF RND pumps (Elkins and Mullis,
2006). Recent studies described the eﬀect that bile salts have on
alerting (signaling) E. coli for the entrance into the small intestine.
In a transcriptomic study designed to further explore the eﬀect
of bile salts on E. coli O157:H7, these were found to induce
signiﬁcant changes in the activation of genes associated with iron
scavenging and metabolism, thereby, preparing the bacteria to
survive in an iron limiting environment (Hamner et al., 2013).
AcrD and AcrF RND eﬄux pumps were reported to be up-
regulated when bacteria are in the sessile state, i.e., bioﬁlm state.
Inhibition of these pumps led to a decrease in bioﬁlm formation
caused by E. coli-causing UTI strains (Kvist et al., 2008). Some
extracellular components of the E. coli bioﬁlm matrix, such as
cellulose, are hydrophilic (Beloin et al., 2008). As it is known
AcrD have speciﬁcity for these substrates. AcrD mutants have
shown to be unable to form bioﬁlms (Matsumura et al., 2011);
these results illustrate the importance of RND eﬄux pumps in
the colonization processes.
Cell-to-cell communication plays an important role in
bacterial stress and cell organization. In vitro assays with
MDR E. coli using lomeﬂoxacin and ceftazidime showed over-
expression of marA and sdiA (Tavío et al., 2010). SdiA is
believed to behave as a quorum sensor in E. coli (Shimada
et al., 2014) that controls the expression of AcrAB (Rahmati
et al., 2002). Although E. coli does not have N-acylhomoserine
lactone system, these bacteria can detect quorum sensing signals
secreted by other organisms. Understanding how RND eﬄux
pumps interact with quorum sensing mechanisms is important
for future development of new compounds capable of inhibiting
bioﬁlm structures and interfering with bacterial cell-to-cell
communication.
“More In and Less Out” – How to
Overcome Resistance Using Inhibitors of
RND Pumps
Once the structure of the RND eﬄux pumps was solved and the
assembling mechanism determined it was possible to start the
rational development of new compounds capable of inhibiting
their function. This could be achieved due to the fact that all the
RND eﬄux systems work in the same way, changing only their
substrates. However, to our knowledge, there are no compounds
capable of inhibiting all RND eﬄux pumps and that could be used
at the present time in clinical practice.
The use of so-called EPIs in combination with antibiotics
(designated as adjuvant therapy) has shown some interesting
results in overcoming the innate and induced resistance of
bacteria due to eﬄux (Bohnert and Kern, 2005). The adjuvant
therapy can be tested by combining the action of an EPI with
an antibiotic or a substrate of a given RND eﬄux pump at sub-
inhibitory concentrations and measuring its eﬄux rate (Coldham
et al., 2010). RND eﬄux pumps can be inhibited by diﬀerent
ways; for example by interfering with the PMF mechanism or by
inhibiting/competing with the binding site of the RND pump.
Inhibition of the PMF can be achieved using a PMF
uncoupler such as carbonyl cyanide m-chlorophenylhydrazone
(CCCP; Viveiros et al., 2005; Ikonomidis et al., 2008). This
compound is mainly used for the screening of RND eﬄux
pumps activity. Other compound, Phenylalanine-Arginine-
β-naphthylamide (PAβN) was identiﬁed as an EPI by assaying
an array of compounds against Pseudomonas aeruginosa
(Lomovskaya et al., 2001). A few years later, PAβN was described
as being not an inhibitor of RND eﬄux pumps, but rather a
competitor (Viveiros et al., 2008). Recently, new data has shown
that PAβN acts as an inhibitor of AcrAB and AcrEF eﬄux systems
when used in low concentrations. At higher concentrations
this compound showed not only inhibitory activity toward the
mentioned eﬄux pumps but also an eﬀect in destabilizing the cell
wall membrane (Misra et al., 2015). PAβN was also found to bind
to the upper portion of the central cavity and also the periplasmic
domain to one side of the deep external cleft (Nikaido and
Takatsuka, 2009). PAβN is known to be a successful compound
in reverting the resistance to tetracycline (Viveiros et al., 2005)
and to macrolides when compared to other known EPIs (Kern
et al., 2006).
In E. coli, compounds such as PAβN, chloramphenicol and
others have been shown to improve the eﬄux of cephalosporins
(Kinana et al., 2013). This eﬀect could be due to the fact that
cephalosporins bind to a diﬀerent site in the large binding pocket
of the RND pump.
Naphthylpiperazines are also one type of RND inhibitor
that could be used to target eﬄux pumps. Speciﬁcally,
1-(1-naphthylmethyl)-piperazine (NMP) is known to have an
inhibitory eﬀect on eﬄux pumps. When used in combination
with ﬂuoroquinolones this compound also showed a reduction
in ﬂuoroquinolone resistance in E. coli (Bohnert and Kern, 2005;
Kern et al., 2006). A similar result was obtained whenMDR E. coli
of animal origin was assessed wherein NMP was able to reverse
resistance to ciproﬂoxacin, tetracycline and ﬂorfenicol. However,
NMP showed to be ineﬃcient in reversing resistance to ampicillin
(Marchetti et al., 2012).
The use of phenothiazines in combination with antibiotics
has also being studied for potential reversal of bacterial
resistance. Chlorpromazine (CPZ) and thioridazine (TZ), known
antipsychotic drugs (Amaral and Molnar, 2012), have been
shown to be active against E. coli (Viveiros et al., 2005). These
compounds also showed to be able to reduce the resistance to
aminoglycosides (Coutinho et al., 2010) as well as the capacity
to be used for plasmid curing (Radhakrishnan et al., 1999;
Spengler et al., 2003). Other recent compounds that should
be considered include pimozide (Bohnert et al., 2013) or the
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speciﬁcally designed MBX2319 (Opperman et al., 2014; Vargiu
et al., 2014) that also proved to have a reducing eﬀect in the
resistance to some antibiotic classes; a similar eﬀect to the one
seen by the previously described EPIs.
Based on the studies described above it seems that the use
of diﬀerent EPIs conducts to diﬀerent results depending on the
antibiotic used in the combination tested. These diﬀerences are
possibly due to the diﬀerent binding sites of each antibiotic/EPI.
Classiﬁcation of the diﬀerent EPIs based on their activity in the
pump or in combination with the diﬀerent antimicrobial classes
could provide essential information for future research.
Final Conclusion
The extensive use of antimicrobials has resulted in an increased
pressure being exerted in diﬀerent ecological niches. Data
collected so far allow us to assume that the resistant proﬁle seen
is not only due to the extensive use of antimicrobials but also
due to the innate capacity of the bacteria to extrude a broad
range of substrates. It is therefore important to characterize eﬄux
pumps and their mechanism of action, in diﬀerent bacteria.
Understanding how eﬄuxmechanisms can contribute to quorum
sensing is of paramount importance for the development of new
molecules that can target key genes or proteins in this cascade.
Regarding RND eﬄux pumps in E. coli the crystal structure of
several pumps such as the MdtABC is crucial for the elucidation
of the binding pockets composition as well as their substrates for
these types of pumps.
In the future, the combined use of EPIs with antibiotics
appears to be a promising therapy to be applied in the ﬁght
against antibiotic resistance. Therefore, the development of new
inhibitor molecules based on the models generated by the crystal
structure of the eﬄux pumps will allow performing a more
target-speciﬁc inhibition.
Acknowledgments
JA research is supported by Grant 11/F/051 provided by the
Department of Agriculture, Food and the Marine (DAFM),
Ireland, under the Food Institutional Research Measure (FIRM)
Network and Team Building Initiative 2006.
MM and SF are members of the translocation consortium
(www.translocation.eu) that has received support from
the Innovative Medicines joint Undertaking under Grant
Agreement n◦115525, resources which are composed of ﬁnancial
contribution from the European Union’s seventh framework
programme (FP/2007-2013) and EFPIA companies in kind
contributions.
References
Aires, J. R., and Nikaido, H. (2005). Aminoglycosides are captured from
both periplasm and cytoplasm by the AcrD multidrug eﬄux transporter
of Escherichia coli. J. Bacteriol. 187, 1923–1929. doi: 10.1128/JB.187.6.1923-
1929.2005
Alvarez-Ortega, C., Olivares, J., and Martínez, J. L. (2013). RND multidrug
eﬄux pumps: what are they good for? Front. Microbiol. 4:7. doi:
10.3389/fmicb.2013.00007
Amaral, L., Fanning, S., and Pagès, J.-M. (2011). Eﬄux pumps of gram-negative
bacteria: genetic responses to stress and the modulation of their activity by
pH, inhibitors, and phenothiazines. Adv. Enzymol. Relat. Areas Mol. Biol. 77,
61–108. doi: 10.1002/9780470920541.ch2
Amaral, L., and Molnar, J. (2012). Why and how thioridazine in combination
with antibiotics to which the infective strain is resistant will cure totally
drug-resistant tuberculosis. Expert Rev. Anti. Infect. Ther. 10, 869–873. doi:
10.1586/eri.12.73
Andersson, D. I., and Hughes, D. (2014). Microbiological eﬀects of sublethal levels
of antibiotics. Nat. Rev. Microbiol. 12, 465–478. doi: 10.1038/nrmicro3270
Bagai, I., Liu, W., Rensing, C., Blackburn, N. J., and McEvoy, M. M.
(2007). Substrate-linked conformational change in the periplasmic component
of a Cu(I)/Ag(I) eﬄux system. J. Biol. Chem. 282, 35695–35702. doi:
10.1074/jbc.M703937200
Baranova, N., and Nikaido, H. (2002). The baeSR two-component regulatory
system activates transcription of the yegMNOB (mdtABCD) transporter
gene cluster in Escherichia coli and increases its resistance to novobiocin
and deoxycholate. J. Bacteriol. 184, 4168–4176. doi: 10.1128/JB.184.15.4168-
4176.2002
Bavro, V. N., Pietras, Z., Furnham, N., Pérez-Cano, L., Fernández-Recio, J.,
Pei, X. Y., et al. (2008). Assembly and channel opening in a bacterial
drug eﬄux machine. Mol. Cell 30, 114–121. doi: 10.1016/j.molcel.2008.
02.015
Beloin, C., Roux, A., and Ghigo, J. M. (2008). Escherichia coli bioﬁlms. Curr. Top.
Microbiol. Immunol. 322, 249–289. doi: 10.1007/978-3-540-75418-3_12
Bohnert, J. A., and Kern, W. V. (2005). Selected arylpiperazines are capable
of reversing multidrug resistance in Escherichia coli overexpressing
RND eﬄux pumps. Antimicrob. Agents Chemother. 49, 849–852. doi:
10.1128/AAC.49.2.849-852.2005
Bohnert, J. A., Schuster, S., and Kern, W. V. (2013). Pimozide inhibits the
AcrAB-TolC eﬄux pump in Escherichia coli. Open Microbiol. J. 7, 83–86. doi:
10.2174/1874285801307010083
Cagnacci, S., Gualco, L., Debbia, E., Schito, G. C., and Marchese, A.
(2008). European emergence of ciproﬂoxacin-resistant Escherichia coli clonal
groups O25:H4-ST 131 and O15:K52:H1 causing community-acquired
uncomplicated cystitis. J. Clin. Microbiol. 46, 2605–2612. doi: 10.1128/JCM.00
640-08
Capita, R., Riesco-Peláez, F., Alonso-Hernando, A., and Alonso-Calleja, C.
(2014). Exposure of Escherichia coli ATCC 12806 to sublethal concentrations
of food-grade biocides inﬂuences its ability to form bioﬁlm, resistance to
antimicrobials, and ultrastructure. Appl. Environ. Microbiol. 80, 1268–1280. doi:
10.1128/AEM.02283-13
Carraro, N., Matteau, D., Luo, P., Rodrigue, S., and Burrus, V. (2014).
The master activator of IncA/C conjugative plasmids stimulates genomic
islands and multidrug resistance dissemination. PLoS Genet. 10:e1004714. doi:
10.1371/journal.pgen.1004714
Castanon, J. I. R. (2007). History of the use of antibiotic as growth promoters in
European poultry feeds Poult. Sci. 86, 2466–2471. doi: 10.3382/ps.2007-00249
Centers for Disease Control and Prevention (CDC). (2006). Ongoing multistate
outbreak of Escherichia coli serotype O157:H7 infections associated with
consumption of fresh spinach–United States, September 2006. MMWR. Morb.
Mortal. Wkly. Rep. 55, 1045–1046.
Chacón, K. N., Mealman, T. D., McEvoy, M. M., and Blackburn, N. J. (2014).
Tracking metal ions through a Cu/Ag eﬄux pump assigns the functional roles
of the periplasmic proteins. Proc. Natl. Acad. Sci. U.S.A. 111, 15373–15378. doi:
10.1073/pnas.1411475111
Coldham, N. G., Webber, M., Woodward, M. J., and Piddock, L. J. V. (2010).
A 96-well plate ﬂuorescence assay for assessment of cellular permeability and
active eﬄux in Salmonella enterica serovar Typhimurium and Escherichia coli.
J. Antimicrob. Chemother. 65, 1655–1663. doi: 10.1093/jac/dkq169
Conroy, O., Kim, E.-H., McEvoy, M. M., and Rensing, C. (2010). Diﬀering ability
to transport nonmetal substrates by two RND-type metal exporters. FEMS
Microbiol. Lett. 308, 115–122. doi: 10.1111/j.1574-6968.2010.02006.x
Frontiers in Microbiology | www.frontiersin.org 10 June 2015 | Volume 6 | Article 587
Anes et al. The ins and outs of RND efflux pumps in Escherichia coli
Coutinho, H. D. M., Costa, J. G. M., Lima, E. O., Falcão-Silva, V. S., and Siqueira-
Júnior, J. P. (2010). Increasing of the aminoglicosyde antibiotic activity against
a multidrug-resistant E. coli by Turnera ulmifolia L. and chlorpromazine. Biol.
Res. Nurs. 11, 332–335. doi: 10.1177/1099800409340052
Delmar, J. A., Su, C.-C., and Yu, E. W. (2013). Structural mechanisms of
heavy-metal extrusion by the Cus eﬄux system. Biometals 26, 593–607. doi:
10.1007/s10534-013-9628-0
Delmar, J. A., Su, C.-C., and Yu, E. W. (2014). Bacterial multidrug eﬄux
transporters. Annu. Rev. Biophys. 43, 93–117. doi: 10.1146/annurev-biophys-
051013-022855
Deng, Z., Shan, Y., Pan, Q., Gao, X., and Yan, A. (2013). Anaerobic expression
of the gadE-mdtEF multidrug eﬄux operon is primarily regulated by the
two-component system ArcBA through antagonizing the H-NS mediated
repression. Front. Microbiol. 4:194. doi: 10.3389/fmicb.2013.00194
Du, D., Wang, Z., James, N. R., Voss, J. E., Klimont, E., Ohene-Agyei, T., et al.
(2014). Structure of the AcrAB-TolC multidrug eﬄux pump. Nature 509,
512–515. doi: 10.1038/nature13205
Elkins, C. A., and Mullis, L. B. (2006). Mammalian steroid hormones are
substrates for the major RND- and MFS-type tripartite multidrug eﬄux pumps
of Escherichia coli. J. Bacteriol. 188, 1191–1195. doi: 10.1128/JB.188.3.1191-
1195.2006
Elkins, C. A., and Nikaido, H. (2002). Substrate speciﬁcity of the RND-type
multidrug eﬄux pumps AcrB and AcrD of Escherichia coli is determined
predominantly by two large periplasmic loops. J. Bacteriol. 184, 6490–6498. doi:
10.1128/JB.184.23.6490-6499.2002
Elkins, C. A., and Nikaido, H. (2003). Chimeric analysis of AcrA function
reveals the importance of its C-terminal domain in its interaction with
the AcrB multidrug eﬄux pump. J. Bacteriol. 185, 5349–5356. doi:
10.1128/JB.185.18.5349-5356.2003
Fadli, M., Chevalier, J., Hassani, L., Mezrioui, N.-E., and Pagès, J.-M.
(2014). Natural extracts stimulate membrane-associated mechanisms of
resistance in Gram-negative bacteria. Lett. Appl. Microbiol. 58, 472–477. doi:
10.1111/lam.12216
Fernandez-Recio, J., Walas, F., Federici, L., Venkatesh Pratap, J., Bavro, V. N.,
Miguel, R. N., et al. (2004). A model of a transmembrane drug-eﬄux pump
from Gram-negative bacteria. FEBS Lett. 578, 5–9. doi: 10.1016/j.febslet.2004.
10.097
Fralick, J. A. (1996). Evidence that TolC is required for functioning of the
Mar/AcrAB eﬄux pump of Escherichia coli. J. Bacteriol. 178, 5803–5805.
Frawley, E. R., Crouch, M.-L. V., Bingham-Ramos, L. K., Robbins, H. F.,
Wang, W., Wright, G. D., et al. (2013). Iron and citrate export by a major
facilitator superfamily pump regulates metabolism and stress resistance in
Salmonella Typhimurium. Proc. Natl. Acad. Sci. U.S.A. 110, 12054–1209. doi:
10.1073/pnas.1218274110
Ge, Q., Yamada, Y., and Zgurskaya, H. (2009). The C-terminal domain of AcrA is
essential for the assembly and function of the multidrug eﬄux pump AcrAB-
TolC. J. Bacteriol. 191, 4365–4371. doi: 10.1128/JB.00204-09
Gilbert, P., and McBain, A. J. (2001). Biocide usage in the domestic setting and
concern about antibacterial and antibiotic resistance. J. Infect. 43, 85–91. doi:
10.1053/jinf.2001.0853
Gillings, M. R. (2014). Integrons: past, present, and future. Microbiol. Mol. Biol.
Rev. 78, 257–277. doi: 10.1128/MMBR.00056-13
Gudipaty, S. A., Larsen, A. S., Rensing, C., and McEvoy, M. M. (2012). Regulation
of Cu(I)/Ag(I) eﬄux genes in Escherichia coli by the sensor kinase CusS. FEMS
Microbiol. Lett. 330, 30–37. doi: 10.1111/j.1574-6968.2012.02529.x
Gunn, J. S. (2001). Bacterial modiﬁcation of LPS and resistance to antimicrobial
peptides. J. Endotoxin Res. 7, 57–62. doi: 10.1177/09680519010070011001
Hamner, S., McInnerney, K.,Williamson, K., Franklin, M. J., and Ford, T. E. (2013).
Bile salts aﬀect expression of Escherichia coli O157:H7 genes for virulence and
iron acquisition, and promote growth under iron limiting conditions. PLoS
ONE 8:e74647. doi: 10.1371/journal.pone.0074647
Hassan, K. A., Elbourne, L. D. H., Li, L., Gamage, H. K. A. H., Liu, Q., Jackson,
S. M., et al. (2015a). An ace up their sleeve: a transcriptomic approach exposes
the AceI eﬄux protein of Acinetobacter baumannii and reveals the drug eﬄux
potential hidden in many microbial pathogens. Front. Microbiol. 6:333. doi:
10.3389/fmicb.2015.00333
Hassan, K. A., Liu, Q., Henderson, P. J. F., and Paulsen, I. T. (2015b).
Homologs of the Acinetobacter baumannii AceI transporter represent a
new family of bacterial multidrug eﬄux systems. MBio 6, e01982-14. doi:
10.1128/mBio.01982-14
Higgins, M. K., Eswaran, J., Edwards, P., Schertler, G. F. X., Hughes, C., and
Koronakis, V. (2004). Structure of the ligand-blocked periplasmic entrance of
the bacterial multidrug eﬄux protein TolC. J. Mol. Biol. 342, 697–702. doi:
10.1016/j.jmb.2004.07.088
Hinchliﬀe, P., Symmons, M. F., Hughes, C., and Koronakis, V. (2013). Structure
and operation of bacterial tripartite pumps. Annu. Rev. Microbiol. 67, 221–242.
doi: 10.1146/annurev-micro-092412-155718
Hirakawa, H., Nishino, K., Yamada, J., Hirata, T., and Yamaguchi, A. (2003). Beta-
lactam resistance modulated by the overexpression of response regulators of
two-component signal transduction systems in Escherichia coli. J. Antimicrob.
Chemother. 52, 576–582. doi: 10.1093/jac/dkg406
Hirakawa, H., Takumi-Kobayashi, A., Theisen, U., Hirata, T., Nishino, K.,
and Yamaguchi, A. (2008). AcrS/EnvR represses expression of the acrAB
multidrug eﬄux genes in Escherichia coli. J. Bacteriol. 190, 6276–6279. doi:
10.1128/JB.00190-08
Hirata, T., Saito, A., Nishino, K., Tamura, N., and Yamaguchi, A. (2004).
Eﬀects of eﬄux transporter genes on susceptibility of Escherichia coli to
tigecycline (GAR-936). Antimicrob. Agents Chemother. 48, 2179–2184. doi:
10.1128/AAC.48.6.2179-2184.2004
Hobbs, E. C., Yin, X., Paul, B. J., Astarita, J. L., and Storz, G. (2012). Conserved
small protein associates with the multidrug eﬄux pump AcrB and diﬀerentially
aﬀects antibiotic resistance. Proc. Natl. Acad. Sci. U.S.A. 109, 16696–16701. doi:
10.1073/pnas.1210093109
Horiyama, T., and Nishino, K. (2014). AcrB, AcrD, and MdtABC multidrug eﬄux
systems are involved in enterobactin export in Escherichia coli. PLoS ONE
9:e108642. doi: 10.1371/journal.pone.0108642
Husain, F., Bikhchandani, M., and Nikaido, H. (2011). Vestibules are part of the
substrate path in the multidrug eﬄux transporter AcrB of Escherichia coli.
J. Bacteriol. 193, 5847–5849. doi: 10.1128/JB.05759-11
Husain, F., and Nikaido, H. (2010). Substrate path in the AcrB multidrug eﬄux
pump of Escherichia coli. Mol. Microbiol. 78, 320–330. doi: 10.1111/j.1365-
2958.2010.07330.x
Ikonomidis, A., Tsakris, A., Kanellopoulou, M., Maniatis, A. N., and Pournaras, S.
(2008). Eﬀect of the proton motive force inhibitor carbonyl cyanide-
m-chlorophenylhydrazone (CCCP) on Pseudomonas aeruginosa bioﬁlm
development. Lett. Appl. Microbiol. 47, 298–302. doi: 10.1111/j.1472-
765X.2008.02430.x
Jellen-Ritter, A. S., and Kern, W. V. (2001). Enhanced expression of the multidrug
eﬄux pumps AcrAB and AcrEF associated with insertion element transposition
in Escherichia colimutants selected with a ﬂuoroquinolone. Antimicrob. Agents
Chemother. 45, 1467–1472. doi: 10.1128/AAC.45.5.1467-1472.2001
Kern, W. V., Steinke, P., Schumacher, A., Schuster, S., von Baum, H., and Bohnert,
J. A. (2006). Eﬀect of 1-(1-naphthylmethyl)-piperazine, a novel putative eﬄux
pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of
Escherichia coli. J. Antimicrob. Chemother. 57, 339–343. doi: 10.1093/jac/dki445
Kim, E.-H., Nies, D. H., McEvoy, M. M., and Rensing, C. (2011). Switch or funnel:
how RND-type transport systems control periplasmic metal homeostasis.
J. Bacteriol. 193, 2381–2387. doi: 10.1128/JB.01323-10
Kim,H.-M., Xu, Y., Lee,M., Piao, S., Sim, S.-H., Ha, N.-C., et al. (2010a). Functional
relationships between the AcrA hairpin tip region and the TolC aperture tip
region for the formation of the bacterial tripartite eﬄux pump AcrAB-TolC.
J. Bacteriol. 192, 4498–4503. doi: 10.1128/JB.00334-10
Kim, H.-S., Nagore, D., and Nikaido, H. (2010b). Multidrug eﬄux pumpMdtBC of
Escherichia coli is active only as a B2C heterotrimer. J. Bacteriol. 192, 1377–1386.
doi: 10.1128/JB.01448-09
Kim, H.-S., and Nikaido, H. (2012). Diﬀerent functions of MdtB and MdtC
subunits in the heterotrimeric eﬄux transporter MdtB(2)C complex of
Escherichia coli. Biochemistry 51, 4188–4197. doi: 10.1021/bi300379y
Kim, J.-S., Jeong, H., Song, S., Kim, H.-Y., Lee, K., Hyun, J., et al. (2015). Structure
of the tripartite multidrug eﬄux pump AcrAB-TolC suggests an alternative
assembly mode.Mol. Cells 38, 180–186. doi: 10.14348/molcells.2015.2277
Kinana, A. D., Vargiu, A. V., and Nikaido, H. (2013). Some ligands enhance
the eﬄux of other ligands by the Escherichia coli multidrug pump AcrB.
Biochemistry 52, 8342–8351. doi: 10.1021/bi401303v
Kobayashi, A., Hirakawa, H., Hirata, T., Nishino, K., and Yamaguchi, A. (2006).
Growth phase-dependent expression of drug exporters in Escherichia coli
Frontiers in Microbiology | www.frontiersin.org 11 June 2015 | Volume 6 | Article 587
Anes et al. The ins and outs of RND efflux pumps in Escherichia coli
and its contribution to drug tolerance. J. Bacteriol. 188, 5693–5703. doi:
10.1128/JB.00217-06
Kobayashi, K., Tsukagoshi, N., and Aono, R. (2001). Suppression of
hypersensitivity of Escherichia coli acrB mutant to organic solvents by
integrational activation of the acrEF operon with the IS1 or IS2 element.
J. Bacteriol. 183, 2646–2653. doi: 10.1128/JB.183.8.2646-2653.2001
Kobayashi, N., Tamura, N., van Veen, H. W., Yamaguchi, A., and Murakami, S.
(2014). β-Lactam selectivity of multidrug transporters AcrB and AcrD resides
in the proximal binding pocket. J. Biol. Chem. 289, 10680–10690. doi:
10.1074/jbc.M114.547794
Koronakis, V., Sharﬀ, A., Koronakis, E., Luisi, B., and Hughes, C. (2000). Crystal
structure of the bacterial membrane protein TolC central to multidrug eﬄux
and protein export. Nature 405, 914–919. doi: 10.1038/35016007
Krishnamoorthy, G., Tikhonova, E. B., Dhamdhere, G., and Zgurskaya, H. I.
(2013). On the role of TolC in multidrug eﬄux: the function and assembly of
AcrAB-TolC tolerate signiﬁcant depletion of intracellular TolC protein. Mol.
Microbiol. 87, 982–997. doi: 10.1111/mmi.12143
Kulathila, R., Kulathila, R., Indic, M., and van den Berg, B. (2011). Crystal structure
of Escherichia coliCusC, the outermembrane component of a heavymetal eﬄux
pump. PLoS ONE 6:e15610. doi: 10.1371/journal.pone.0015610
Kvist, M., Hancock, V., and Klemm, P. (2008). Inactivation of eﬄux pumps
abolishes bacterial bioﬁlm formation. Appl. Environ. Microbiol. 74, 7376–7382.
doi: 10.1128/AEM.01310-08
Lamikanra, A., Crowe, J. L., Lijek, R. S., Odetoyin, B. W., Wain, J., Aboderin, A.
O., et al. (2011). Rapid evolution of ﬂuoroquinolone-resistant Escherichia coli
in Nigeria is temporally associated with ﬂuoroquinolone use. BMC Infect. Dis.
11:312. doi: 10.1186/1471-2334-11-312
Lau, S. Y., and Zgurskaya, H. I. (2005). Cell division defects in Escherichia coli
deﬁcient in the multidrug eﬄux transporter AcrEF-TolC. J. Bacteriol. 187,
7815–7825. doi: 10.1128/JB.187.22.7815-7825.2005
Lee, A., Mao, W., Warren, M. S., Mistry, A., Hoshino, K., Okumura, R.,
et al. (2000). Interplay between eﬄux pumps may provide either additive
or multiplicative eﬀects on drug resistance. J. Bacteriol. 182, 3142–3150. doi:
10.1128/JB.182.11.3142-3150.2000
Lennen, R. M., Politz, M. G., Kruziki, M. A., and Pﬂeger, B. F. (2013). Identiﬁcation
of transport proteins involved in free fatty acid eﬄux in Escherichia coli.
J. Bacteriol. 195, 135–144. doi: 10.1128/JB.01477-12
Li, X.-Z., and Nikaido, H. (2009). Eﬄux-mediated drug resistance in bacteria: an
update. Drugs 69, 1555–1623. doi: 10.2165/11317030-000000000-00000
Li, X.-Z., Plésiat, P., and Nikaido, H. (2015). The challenge of eﬄux-mediated
antibiotic resistance in Gram-negative bacteria. Clin. Microbiol. Rev. 28, 337–
418. doi: 10.1128/CMR.00117-14
Lobedanz, S., Bokma, E., Symmons, M. F., Koronakis, E., Hughes, C., and
Koronakis, V. (2007). A periplasmic coiled-coil interface underlying TolC
recruitment and the assembly of bacterial drug eﬄux pumps. Proc. Natl. Acad.
Sci. U.S.A. 104, 4612–4617. doi: 10.1073/pnas.0610160104
Loftin, I. R., Franke, S., Blackburn, N. J., and McEvoy, M. M. (2007). Unusual
Cu(I)/Ag(I) coordination of Escherichia coli CusF as revealed by atomic
resolution crystallography and X-ray absorption spectroscopy. Protein Sci. 16,
2287–2293. doi: 10.1110/ps.073021307
Loftin, I. R., Franke, S., Roberts, S. A., Weichsel, A., Héroux, A., Montfort, W. R.,
et al. (2005). A novel copper-binding fold for the periplasmic copper resistance
protein CusF. Biochemistry 44, 10533–10540. doi: 10.1021/bi050827b
Lomovskaya, O., Warren, M. S., Lee, A., Galazzo, J., Fronko, R., Lee, M.,
et al. (2001). Identiﬁcation and characterization of inhibitors of multidrug
resistance eﬄux pumps in Pseudomonas aeruginosa: novel agents for
combination therapy. Antimicrob. Agents Chemother. 45, 105–116. doi:
10.1128/AAC.45.1.105-116.2001
Long, F., Su, C.-C., Lei, H.-T., Bolla, J. R., Do, S. V., and Yu, E. W. (2012). Structure
and mechanism of the tripartite CusCBA heavy-metal eﬄux complex. Philos.
Trans. R. Soc. Lond. B Biol. Sci. 367, 1047–1058. doi: 10.1098/rstb.2011.0203
Long, F., Su, C.-C., Zimmermann, M. T., Boyken, S. E., Rajashankar, K. R.,
Jernigan, R. L., et al. (2010). Crystal structures of the CusA eﬄux pump
suggest methionine-mediated metal transport. Nature 467, 484–488. doi:
10.1038/nature09395
Lu, S., and Zgurskaya, H. I. (2012). Role of ATP binding and hydrolysis in assembly
of MacAB-TolC macrolide transporter. Mol. Microbiol. 86, 1132–1143. doi:
10.1111/mmi.12046
Lubelski, J., Konings, W. N., and Driessen, A. J. M. (2007). Distribution and
physiology of ABC-type transporters contributing to multidrug resistance in
bacteria. Microbiol. Mol. Biol. Rev. 71, 463–476. doi: 10.1128/MMBR.00001-07
Marchetti, M. L., Errecalde, J., and Mestorino, N. (2012). Eﬀect of 1-(1-
naphthylmethyl)-piperazine on antimicrobial agent susceptibility inmultidrug-
resistant isogenic and veterinary Escherichia coli ﬁeld strains. J. Med. Microbiol.
61, 786–792. doi: 10.1099/jmm.0.040204-0
Martins, A., Spengler, G., Rodrigues, L., Viveiros, M., Ramos, J., Martins, M.,
et al. (2009). pH Modulation of eﬄux pump activity of multi-drug
resistant Escherichia coli: protection during its passage and eventual
colonization of the colon. PLoS ONE 4:e6656. doi: 10.1371/journal.pone.
0006656
Masi, M., and Pagès, J.-M. (2013). Structure, function and regulation of outer
membrane proteins involved in drug transport in Enterobactericeae:
the OmpF/C - TolC case. Open Microbiol. J. 7, 22–33. doi:
10.2174/1874285801307010022
Matsumura, K., Furukawa, S., Ogihara, H., and Morinaga, Y. (2011). Roles of
multidrug eﬄux pumps on the bioﬁlm formation of Escherichia coli K-12.
Biocontrol Sci. 16, 69–72. doi: 10.4265/bio.16.69
Matsumura, Y., Yamamoto, M., Nagao, M., Ito, Y., Takakura, S., and Ichiyama, S.
(2013). Association of ﬂuoroquinolone resistance, virulence genes, and
IncF plasmids with extended-spectrum-β-lactamase-producing Escherichia coli
sequence type 131 (ST131) and ST405 clonal groups. Antimicrob. Agents
Chemother. 57, 4736–4742. doi: 10.1128/AAC.00641-13
Mealman, T. D., Zhou, M., Aﬀandi, T., Chacón, K. N., Aranguren, M. E.,
Blackburn, N. J., et al. (2012). N-terminal region of CusB is suﬃcient for metal
binding and metal transfer with the metallochaperone CusF. Biochemistry 51,
6767–6775. doi: 10.1021/bi300596a
Merritt, M. E., and Donaldson, J. R. (2009). Eﬀect of bile salts on the DNA and
membrane integrity of enteric bacteria. J. Med. Microbiol. 58, 1533–1541. doi:
10.1099/jmm.0.014092-0
Michael, C. A., Dominey-Howes, D., and Labbate, M. (2014). The antimicrobial
resistance crisis: causes, consequences, and management. Front. Public Health
2:145. doi: 10.3389/fpubh.2014.00145
Misra, R., Morrison, K. D., Cho, H. J., and Khuu, T. (2015). Importance of real-time
assays to distinguish multidrug eﬄux pump inhibiting and outer membrane
destabilizing activities in Escherichia coli. J. Bacteriol. doi: 10.1128/JB.02456-14
[Epub ahead of print].
Money, P., Kelly, A. F., Gould, S. W. J., Denholm-Price, J., Threlfall, E. J., and
Fielder, M. D. (2010). Cattle, weather and water: mapping Escherichia coli
O157:H7 infections in humans in England and Scotland. Environ. Microbiol.
12, 2633–2644. doi: 10.1111/j.1462-2920.2010.02293.x
Moon, D. C., Seol, S. Y., Gurung, M., Jin, J. S., Choi, C. H., Kim, J.,
et al. (2010). Emergence of a new mutation and its accumulation in the
topoisomerase IV gene confers high levels of resistance to ﬂuoroquinolones
in Escherichia coli isolates. Int. J. Antimicrob. Agents 35, 76–79. doi:
10.1016/j.ijantimicag.2009.08.003
Murakami, S., Nakashima, R., Yamashita, E., Matsumoto, T., and Yamaguchi, A.
(2006). Crystal structures of a multidrug transporter reveal a functionally
rotating mechanism. Nature 443, 173–179. doi: 10.1038/nature
05076
Murakami, S., Nakashima, R., Yamashita, E., and Yamaguchi, A. (2002). Crystal
structure of bacterial multidrug eﬄux transporter AcrB. Nature 419, 587–593.
doi: 10.1038/nature01050
Nagakubo, S., Nishino, K., Hirata, T., and Yamaguchi, A. (2002). The putative
response regulator BaeR stimulates multidrug resistance of Escherichia coli via
a novel multidrug exporter system, MdtABC. J. Bacteriol. 184, 4161–4167. doi:
10.1128/JB.184.15.4161-4167.2002
Nakashima, R., Sakurai, K., Yamasaki, S., Nishino, K., and Yamaguchi, A. (2011).
Structures of the multidrug exporter AcrB reveal a proximal multisite drug-
binding pocket. Nature 480, 565–569. doi: 10.1038/nature10641
Nies, D. H. (2003). Eﬄux-mediated heavy metal resistance in prokaryotes. FEMS
Microbiol. Rev. 27, 313–339. doi: 10.1016/S0168-6445(03)00048-2
Nikaido, H. (1996). Multidrug eﬄux pumps of gram-negative bacteria. J. Bacteriol.
178, 5853–5859.
Nikaido, H. (2011). Structure and mechanism of RND-type multidrug
eﬄux pumps. Adv. Enzymol. Relat. Areas Mol. Biol. 77, 1–60. doi:
10.1002/9780470920541.ch1
Frontiers in Microbiology | www.frontiersin.org 12 June 2015 | Volume 6 | Article 587
Anes et al. The ins and outs of RND efflux pumps in Escherichia coli
Nikaido, H., and Pagès, J. -M. (2012). Broad-speciﬁcity eﬄux pumps and their role
in multidrug resistance of Gram-negative bacteria. FEMS Microbiol. Rev. 36,
340–363. doi: 10.1111/j.1574-6976.2011.00290.x
Nikaido, H., and Takatsuka, Y. (2009). Mechanisms of RND
multidrug eﬄux pumps. Biochim. Biophys. Acta 1794, 769–781. doi:
10.1016/j.bbapap.2008.10.004
Nishino, K., Senda, Y., Hayashi-Nishino, M., and Yamaguchi, A. (2009). Role of the
AraC-XylS family regulator YdeO in multi-drug resistance of Escherichia coli.
J. Antibiot. (Tokyo) 62, 251–257. doi: 10.1038/ja.2009.23
Nishino, K., Senda, Y., and Yamaguchi, A. (2008a). CRP regulator modulates
multidrug resistance of Escherichia coli by repressing the mdtEF multidrug
eﬄux genes. J. Antibiot. (Tokyo) 61, 120–127. doi: 10.1038/ja.2008.120
Nishino, K., Senda, Y., and Yamaguchi, A. (2008b). The AraC-family regulator
GadX enhances multidrug resistance in Escherichia coli by activating expression
of mdtEF multidrug eﬄux genes. J. Infect. Chemother. 14, 23–29. doi:
10.1007/s10156-007-0575-Y
Nishino, K., and Yamaguchi, A. (2001). Analysis of a complete library of putative
drug transporter genes in Escherichia coli. J. Bacteriol. 183, 5803–5812. doi:
10.1128/JB.183.20.5803-5812.2001
Nishino, K., and Yamaguchi, A. (2002). EvgA of the two-component signal
transduction systemmodulates production of the YhiUVmultidrug transporter
in Escherichia coli. J. Bacteriol. 184, 2319–2323. doi: 10.1128/JB.184.8.2319-
2323.2002
Nishino, K., and Yamaguchi, A. (2004). Role of histone-like protein H-NS in
multidrug resistance of Escherichia coli. J. Bacteriol. 186, 1423–1429. doi:
10.1128/JB.186.5.1423-1429.2004
Nishino, K., Yamasaki, S., Hayashi-Nishino, M., and Yamaguchi, A. (2010). Eﬀect
of NlpE overproduction onmultidrug resistance in Escherichia coli.Antimicrob.
Agents Chemother. 54, 2239–2243. doi: 10.1128/AAC.01677-09
Nishino, K., Yamasaki, S., Hayashi-Nishino, M., and Yamaguchi, A. (2011). Eﬀect
of overexpression of small non-coding DsrA RNA on multidrug eﬄux in
Escherichia coli. J. Antimicrob. Chemother. 66, 291–296. doi: 10.1093/jac/
dkq420
Olesen, B., Hansen, D. S., Nilsson, F., Frimodt-Møller, J., Leihof, R. F., Struve, C.,
et al. (2013). Prevalence and characteristics of the epidemic multiresistant
Escherichia coli ST131 clonal group among extended-spectrum beta-lactamase-
producing E. coli isolates in Copenhagen, Denmark. J. Clin. Microbiol. 51,
1779–1785. doi: 10.1128/JCM.00346-13
Opperman, T. J., Kwasny, S. M., Kim, H.-S., Nguyen, S. T., Houseweart, C.,
D’Souza, S., et al. (2014). Characterization of a novel pyranopyridine inhibitor
of the AcrAB eﬄux pump of Escherichia coli.Antimicrob. Agents Chemother. 58,
722–733. doi: 10.1128/AAC.01866-13
Peltier, E., Vincent, J., Finn, C., and Graham, D.W. (2010). Zinc-induced antibiotic
resistance in activated sludge bioreactors. Water Res. 44, 3829–3836. doi:
10.1016/j.watres.2010.04.041
Pennington, T. H. (2014). E. coli O157 outbreaks in the United Kingdom:
past, present, and future. Infect. Drug Resist. 7, 211–222. doi: 10.2147/IDR.S
49081
Perreten, V., Schwarz, F. V., Teuber, M., and Levy, S. B. (2001). Mdt(A), a
new eﬄux protein conferring multiple antibiotic resistance in Lactococcus
lactis and Escherichia coli. Antimicrob. Agents Chemother. 45, 1109–1114. doi:
10.1128/AAC.45.4.1109-1114.2001
Piddock, L. J. V. (2006).Multidrug-resistance eﬄux pumps - not just for resistance.
Nat. Rev. Microbiol. 4, 629–636. doi: 10.1038/nrmicro1464
Poole, K. (2002). Mechanisms of bacterial biocide and antibiotic resistance. J. Appl.
Microbiol. 92(Suppl. s1), 55S–64S. doi: 10.1046/j.1365-2672.92.5s1.8.x
Poole, K. (2007). Eﬄux pumps as antimicrobial resistance mechanisms. Ann. Med.
39, 162–176. doi: 10.1080/07853890701195262
Pos, K. M. (2009). Drug transport mechanism of the AcrB eﬄux pump. Biochim.
Biophys. Acta 1794, 782–793. doi: 10.1016/j.bbapap.2008.12.015
Rademacher, C., and Masepohl, B. (2012). Copper-responsive gene regulation in
bacteria. Microbiology 158, 2451–2464. doi: 10.1099/mic.0.058487-0
Radhakrishnan, V., Ganguly, K., Ganguly, M., Dastidar, S. G., and Chakrabarty,
A. N. (1999). Potentiality of tricyclic compound thioridazine as an eﬀective
antibacterial and antiplasmid agent. Indian J. Exp. Biol. 37, 671–675.
Radosavljevic, V., Finke, E.-J., and Belojevic, G. (2014). Escherichia coli O104:H4
outbreak in Germany–clariﬁcation of the origin of the epidemic. Eur. J. Public
Health 25, 125–129. doi: 10.1093/eurpub/cku048
Rahmati, S., Yang, S., Davidson, A. L., and Zechiedrich, E. L. (2002). Control of
the AcrAB multidrug eﬄux pump by quorum-sensing regulator SdiA. Mol.
Microbiol. 43, 677–685. doi: 10.1046/j.1365-2958.2002.02773.x
Rosenberg, E. Y., Bertenthal, D., Nilles, M. L., Bertrand, K. P., and Nikaido, H.
(2003). Bile salts and fatty acids induce the expression of Escherichia coliAcrAB
multidrug eﬄux pump through their interaction with Rob regulatory protein.
Mol. Microbiol. 48, 1609–1619. doi: 10.1046/j.1365-2958.2003.03531.x
Rosenberg, E. Y., Ma, D., and Nikaido, H. (2000). AcrD of Escherichia
coli is an aminoglycoside eﬄux pump. J. Bacteriol. 182, 1754–1756. doi:
10.1128/JB.182.6.1754-1756.2000
Rosner, J. L., and Martin, R. G. (2009). An excretory function for the Escherichia
coli outer membrane pore TolC: upregulation of marA and soxS transcription
and Rob activity due to metabolites accumulated in tolC mutants. J. Bacteriol.
191, 5283–5292. doi: 10.1128/JB.00507-09
Ruiz, C., and Levy, S. B. (2014). Regulation of acrAB expression by cellular
metabolites in Escherichia coli. J. Antimicrob. Chemother. 69, 390–399. doi:
10.1093/jac/dkt352
Seeger, M. A., Schiefner, A., Eicher, T., Verrey, F., Diederichs, K., and
Pos, K. M. (2006). Structural asymmetry of AcrB trimer suggests a
peristaltic pump mechanism. Science 313, 1295–1298. doi: 10.1126/science.11
31542
Sennhauser, G., Amstutz, P., Briand, C., Storchenegger, O., and Grütter, M. G.
(2007). Drug export pathway of multidrug exporter AcrB revealed by DARPin
inhibitors. PLoS Biol. 5:e7. doi: 10.1371/journal.pbio.0050007
Shah, A. A., Wang, C., Chung, Y.-R., Kim, J.-Y., Choi, E.-S., and Kim, S.-W. (2013).
Enhancement of geraniol resistance of Escherichia coli byMarA overexpression.
J. Biosci. Bioeng. 115, 253–258. doi: 10.1016/j.jbiosc.2012.10.009
Shimada, T., Shimada, K., Matsui, M., Kitai, Y., Igarashi, J., Suga, H., et al. (2014).
Roles of cell division control factor SdiA: recognition of quorum sensing signals
andmodulation of transcription regulation targets.Genes Cells 19, 405–418. doi:
10.1111/gtc.12139
Spengler, G., Miczák, A., Hajdú, E., Kawase, M., Amaral, L., and Molnár, J. (2003).
Enhancement of plasmid curing by 9-aminoacridine and two phenothiazines
in the presence of proton pump inhibitor 1-(2-benzoxazolyl)-3,3,3-triﬂuoro-
2-propanone. Int. J. Antimicrob. Agents 22, 223–227. doi: 10.1016/S0924-
8579(03)00207-3
Su, C.-C., Long, F., Lei, H.-T., Bolla, J. R., Do, S. V., Rajashankar, K. R., et al.
(2012). Charged amino acids (R83, E567, D617, E625, R669, and K678) of CusA
are required for metal ion transport in the Cus eﬄux system. J. Mol. Biol. 422,
429–441. doi: 10.1016/j.jmb.2012.05.038
Su, C.-C., Long, F., and Yu, E. W. (2011a). The Cus eﬄux system removes toxic
ions via a methionine shuttle. Protein Sci. 20, 6–18. doi: 10.1002/pro.532
Su, C.-C., Long, F., Zimmermann, M. T., Rajashankar, K. R., Jernigan, R. L., and
Yu, E. W. (2011b). Crystal structure of the CusBA heavy-metal eﬄux complex
of Escherichia coli. Nature 470, 558–562. doi: 10.1038/nature09743
Su, C.-C., Yang, F., Long, F., Reyon, D., Routh, M. D., Kuo, D. W., et al. (2009).
Crystal structure of the membrane fusion protein CusB from Escherichia coli.
J. Mol. Biol. 393, 342–355. doi: 10.1016/j.jmb.2009.08.029
Sulavik, M. C., Houseweart, C., Cramer, C., Jiwani, N., Murgolo, N., Greene, J.,
et al. (2001). Antibiotic susceptibility proﬁles of Escherichia coli strains lacking
multidrug eﬄux pump genes. Antimicrob. Agents Chemother. 45, 1126–1136.
doi: 10.1128/AAC.45.4.1126-1136.2001
Symmons, M. F., Bokma, E., Koronakis, E., Hughes, C., and Koronakis, V.
(2009). The assembled structure of a complete tripartite bacterial
multidrug eﬄux pump. Proc. Natl. Acad. Sci. U.S.A. 106, 7173–7178. doi:
10.1073/pnas.0900693106
Tal, N., and Schuldiner, S. (2009). A coordinated network of transporters with
overlapping speciﬁcities provides a robust survival strategy. Proc. Natl. Acad.
Sci. U.S.A. 106, 9051–9056. doi: 10.1073/pnas.0902400106
Tanabe, M., Szakonyi, G., Brown, K. A., Henderson, P. J. F., Nield, J., and Byrne, B.
(2009). The multidrug resistance eﬄux complex, EmrAB from Escherichia coli
forms a dimer in vitro. Biochem. Biophys. Res. Commun. 380, 338–342. doi:
10.1016/j.bbrc.2009.01.081
Tavío, M. M., Aquili, V. D., Poveda, J. B., Antunes, N. T., Sánchez-
Céspedes, J., and Vila, J. (2010). Quorum-sensing regulator sdiA and
marA overexpression is involved in in vitro-selected multidrug resistance of
Escherichia coli. J. Antimicrob. Chemother. 65, 1178–1186. doi: 10.1093/jac/
dkq112
Frontiers in Microbiology | www.frontiersin.org 13 June 2015 | Volume 6 | Article 587
Anes et al. The ins and outs of RND efflux pumps in Escherichia coli
Thanassi, D. G., Cheng, L. W., and Nikaido, H. (1997). Active eﬄux of bile salts by
Escherichia coli. J. Bacteriol. 179, 2512–2518.
Tikhonova, E. B., Dastidar, V., Rybenkov, V. V., and Zgurskaya, H. I. (2009).
Kinetic control of TolC recruitment by multidrug eﬄux complexes. Proc. Natl.
Acad. Sci. U.S.A. 106, 16416–16421. doi: 10.1073/pnas.090601106
Tikhonova, E. B., Yamada, Y., and Zgurskaya, H. I. (2011). Sequential mechanism
of assembly of multidrug eﬄux pump AcrAB-TolC. Chem. Biol. 18, 454–463.
doi: 10.1016/j.chembiol.2011.02.011
Tikhonova, E. B., and Zgurskaya, H. I. (2004). AcrA, AcrB, and TolC of Escherichia
coli form a stable intermembrane multidrug eﬄux complex. J. Biol. Chem. 279,
32116–32124. doi: 10.1074/jbc.M402230200
Touzé, T., Eswaran, J., Bokma, E., Koronakis, E., Hughes, C., and Koronakis, V.
(2004). Interactions underlying assembly of the Escherichia coli AcrAB-TolC
multidrug eﬄux system. Mol. Microbiol. 53, 697–706. doi: 10.1111/j.1365-
2958.2004.04158.x
Turlin, E., Heuck, G., Brandão, M. I. S., Szili, N., Mellin, J. R., Lange, N., et al.
(2014). Protoporphyrin (PPIX) eﬄux by the MacAB-TolC pump in Escherichia
coli.Microbiologyopen 3, 849–859. doi: 10.1002/mbo3.203
Vargiu, A. V., Ruggerone, P., Opperman, T. J., Nguyen, S. T., and Nikaido, H.
(2014). Molecular mechanism of MBX2319 inhibition of Escherichia coli AcrB
multidrug eﬄux pump and comparison with other inhibitors. Antimicrob.
Agents Chemother. 58, 6224–6234. doi: 10.1128/AAC.03283-14
Viveiros, M., Jesus, A., Brito, M., Leandro, C., Martins, M., Ordway, D., et al.
(2005). Inducement and reversal of tetracycline resistance in Escherichia coli K-
12 and expression of proton gradient-dependent multidrug eﬄux pump genes.
Antimicrob. Agents Chemother. 49, 3578–3582. doi: 10.1128/AAC.49.8.3578-
3582.2005
Viveiros, M., Martins, A., Paixão, L., Rodrigues, L., Martins, M., Couto, I., et al.
(2008). Demonstration of intrinsic eﬄux activity of Escherichia coliK-12 AG100
by an automated ethidium bromide method. Int. J. Antimicrob. Agents 31,
458–462. doi: 10.1016/j.ijantimicag.2007.12.015
Wang, D., and Fierke, C. A. (2013). The BaeSR regulon is involved in defense
against zinc toxicity in E. coli.Metallomics 5, 372–383. doi: 10.1039/c3mt20217h
Wang, H., Dzink-Fox, J. L., Chen, M., and Levy, S. B. (2001). Genetic
characterization of highly ﬂuoroquinolone-resistant clinical Escherichia coli
strains from China: role of acrR mutations. Antimicrob. Agents Chemother. 45,
1515–1521. doi: 10.1128/AAC.45.5.1515-1521.2001
Warner, D. M., and Levy, S. B. (2010). Diﬀerent eﬀects of transcriptional
regulators MarA, SoxS and Rob on susceptibility of Escherichia coli to cationic
antimicrobial peptides (CAMPs): rob-dependent CAMP induction of the
marRAB operon.Microbiology 156, 570–578. doi: 10.1099/mic.0.033415-0
Weeks, J. W., Celaya-Kolb, T., Pecora, S., and Misra, R. (2010). AcrA suppressor
alterations reverse the drug hypersensitivity phenotype of a TolC mutant
by inducing TolC aperture opening. Mol. Microbiol. 75, 1468–1483. doi:
10.1111/j.1365-2958.2010.07068.x
Wei, Y., Lee, J. M., Smulski, D. R., and LaRossa, R. A. (2001). Global impact
of sdiA ampliﬁcation revealed by comprehensive gene expression proﬁling
of Escherichia coli. J. Bacteriol. 183, 2265–2272. doi: 10.1128/JB.183.7.2265-
2272.2001
World Health Organization (WHO). (2014). Antimicrobial Resistance: Global
Report on Surveillance 2014. Geneva: WHO.
Xu, Y., Lee, M., Moeller, A., Song, S., Yoon, B.-Y., Kim, H.-M., et al. (2011).
Funnel-like hexameric assembly of the periplasmic adapter protein in the
tripartite multidrug eﬄux pump in gram-negative bacteria. J. Biol. Chem. 286,
17910–17920. doi: 10.1074/jbc.M111.238535
Xu, Y., Moeller, A., Jun, S.-Y., Le, M., Yoon, B.-Y., Kim, J.-S., et al. (2012).
Assembly and channel opening of outer membrane protein in tripartite drug
eﬄux pumps of Gram-negative bacteria. J. Biol. Chem. 287, 11740–11750. doi:
10.1074/jbc.M111.329375
Xue, Y., Davis, A. V., Balakrishnan, G., Stasser, J. P., Staehlin, B. M., Focia, P., et al.
(2008). Cu(I) recognition via cation-pi and methionine interactions in CusF.
Nat. Chem. Biol. 4, 107–109. doi: 10.1038/nchembio.2007.57
Yang, D., Weatherspoon-Griﬃn, N., Kong, W., Hua, Z., and Shi, Y. (2014).
The CpxR/CpxA two-component regulatory system upregulates the
multidrug resistance cascade to facilitate Escherichia coli resistance to
a model antimicrobial peptide. J. Biol. Chem. 289, 32571–32582. doi:
10.1074/jbc.M114.565762
Yu, E. W., McDermott, G., Zgurskaya, H. I., Nikaido, H., and Koshland,
D. E. (2003). Structural basis of multiple drug-binding capacity of the
AcrB multidrug eﬄux pump. Science 300, 976–980. doi: 10.1126/science.10
83137
Yum, S., Xu, Y., Piao, S., Sim, S.-H., Kim, H.-M., Jo, W.-S., et al. (2009).
Crystal structure of the periplasmic component of a tripartite macrolide-
speciﬁc eﬄux pump. J. Mol. Biol. 387, 1286–1297. doi: 10.1016/j.jmb.2009.
02.048
Zgurskaya, H. I., and Nikaido, H. (2000). Cross-linked complex between
oligomeric periplasmic lipoprotein AcrA and the inner-membrane-associated
multidrug eﬄux pump AcrB from Escherichia coli. J. Bacteriol. 182, 4264–4267.
doi: 10.1128/JB.182.15.4264-4267.2000
Zhang, Y., Xiao, M., Horiyama, T., Zhang, Y., Li, X., Nishino, K., et al. (2011). The
multidrug eﬄux pump MdtEF protects against nitrosative damage during the
anaerobic respiration in Escherichia coli. J. Biol. Chem. 286, 26576–26584. doi:
10.1074/jbc.M111.243261
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or ﬁnancial relationships that could
be construed as a potential conﬂict of interest.
Copyright © 2015 Anes, McCusker, Fanning and Martins. This is an open-access
article distributed under the terms of the Creative Commons Attribution License
(CC BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Microbiology | www.frontiersin.org 14 June 2015 | Volume 6 | Article 587
